Clarivate explores sale of Life Sciences & Healthcare business
Clarivate has announced that it is pursuing a sale of its Life Sciences & Healthcare business following a strategic review of its portfolio.
The company has appointed Morgan Stanley & Co. LLC as financial advisor and confirmed it is engaged in active discussions with interested parties.
Clarivate said a potential divestment would enable it to increase its focus on its core Academia & Government and Intellectual Property markets. In a statement accompanying its full-year results for 2025, the company indicated that proceeds from any transaction would be used to strengthen its balance sheet, primarily through a reduction in leverage.
As a result, the company’s share price jumped by almost 40%, rising from $1.68 per share to $2.35 per share.
“There can be no assurances that the sale process will result in a transaction,” Clarivate noted, adding that it does not intend to comment further unless additional disclosure is deemed appropriate.
The move signals a continued strategic repositioning for Clarivate, with greater emphasis on its established research, analytics, and IP services businesses serving academic institutions, governments, and innovation-driven organisations globally.